Related Experiment Video
Updated: Jul 19, 2026
Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
Published on: November 11, 2018
Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel
1Department of Cardiology, Cardiovascular Institute and Fu-Wai Heart Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Insights
Simvastatin treatment significantly improves blood flow restoration to ischemic heart tissue by activating mitochondrial K(ATP) channels. This cholesterol-lowering drug reduces no-reflow area and myocardial necrosis after ischemia and reperfusion.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Myocardial Ischemia
Background:
- Simvastatin, a cholesterol-lowering drug, is known to protect against endothelial dysfunction.
- The impact of simvastatin on restoring blood flow to ischemic myocardium remains unclear.
- Understanding simvastatin's effects on myocardial no-reflow is crucial for cardiovascular therapeutics.
Purpose of the Study:
- To evaluate the effects of simvastatin on myocardial no-reflow in an experimental model.
- To investigate the underlying mechanisms by which simvastatin influences blood flow restoration.
- To determine the role of specific K(ATP) channels in simvastatin's cardioprotective effects.
Main Methods:
- A mini-pig model of myocardial no-reflow was established using coronary artery occlusion followed by reperfusion.
- Animals were randomized into groups receiving simvastatin, mitochondrial K(ATP) channel blocker (5-hydroxydecanoate), sarcolemmal K(ATP) channel blocker (HMR 1883), or combinations thereof.
- Myocardial contrast echocardiography and histology were used to assess coronary blood flow, no-reflow area, and necrotic area.
Main Results:
- Simvastatin treatment significantly increased coronary blood flow and decreased the no-reflow and necrotic areas compared to controls.
- The beneficial effects of simvastatin were comparable to those observed with simvastatin combined with the sarcolemmal K(ATP) channel blocker (HMR 1883).
- The mitochondrial K(ATP) channel blocker (5-hydroxydecanoate) abolished the protective effects of simvastatin, indicating its crucial role.
Conclusions:
- Simvastatin effectively reduces myocardial no-reflow and necrosis following ischemia and reperfusion.
- The cardioprotective mechanism of simvastatin involves the activation of mitochondrial K(ATP) channels.
- Targeting mitochondrial K(ATP) channels with simvastatin represents a promising therapeutic strategy for ischemic heart conditions.
Background And Purpose:
Simvastatin, a cholesterol-lowering agent, can protect against endothelial dysfunction. However, the effects of simvastatin treatment on the restoration of blood flow to ischemic myocardium are not known. This study sought to assess such effects of simvastatin on an experimental model of myocardial no-reflow and to explore possible mechanisms.
Experimental Approach:
Coronary ligation area and area of no-reflow were determined by myocardial contrast echocardiography in vivo and by histology in mini-pigs randomized into 7 study groups: controls, pretreated with simvastatin for 2 days, treated with 5-hydroxydecanoate (5-HD, the selective mitochondrial K(ATP) channel blocker), treated with simvastatin+5-HD, treated with HMR 1883 (the selective sarcolemmal K(ATP) channel blocker), treated with simvastatin+HMR 1883 and a sham-operated group. The myocardial no-reflow model was induced with 3 h occlusion of the left anterior descending coronary artery followed by 2 h reperfusion.
Key Results:
Compared with the control group, simvastatin significantly increased coronary blood flow, decreased the area of no-reflow assessed echocardiographically and reduced the necrotic area, by histology. There was no significant difference in these outcomes between simvastatin and simvastatin+HMR 1883 groups. In contrast, 5-HD abolished the effect of simvastatin.
Conclusions And Implications:
Simvastatin can reduce the area and myocardial no-reflow after ischaemia and reperfusion. This beneficial effect is due to its activation of mitochondrial K(ATP) channels.
